Bayer’s (BAYN GY) Asundexian demonstrated a 26% reduction in stroke following non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding compared with placebo”

Bayer’s (BAYN GY) Asundexian demonstrated a 26% reduction in stroke following non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding compared with placebo”

Bayer's Asundexian data showing a 26% reduction in stroke risk without a corresponding increase in major bleeding suggests a significant advancement in their product pipeline. This positive outcome could enhance Bayer's competitive position in the pharmaceuticals sector, potentially boosting investor sentiment and supporting the stock price, especially if the market views this as a catalyst for future sales growth.